Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease.

Recs

1
Player Avatar sandybdr (81.19) Submitted: 8/16/2011 4:15:58 PM : Outperform Start Price: $1.30 LXRX Score: -101.75

Biopharma company that works on mouse genetics , localizes potential drug targets , and then attempts to make drugs specific for those targets. Completely speculative play. If LX4211 succeeds (phase IIb trial currently enroling; results available in 2012) then it would get partnered with big pharma. That being said, a similar drug from Astra Zeneca just got shot down by the FDA.I would peg their chance of success at 1 in 3. They do have 3 more in the pipeline , 2 for irritable bowel syndrone and one for rheumatoid arthritis.Chance of a further dilution before the end of the year ~ 100%chance of being partnered or bought out by big pharma for a successful drug ~ 25%If the pipeline falls through, chance of going to zero by late 2012~ 100% !!!!Worth a speculative flier, the underlying technology and methodology is completely sound.... Though not necessarily enough to ensure success!

Featured Broker Partners


Advertisement